SciGen Technologies is a proud partner in the ThrombUS+ project, a Horizon Europe-funded venture to create a diagnostic wearable device capable of detecting deep vein thrombosis (DVT).
ThrombUS+ kicked off on January 1, 2024, and will conclude on June 30, 2027. The project has 18 partners from Greece, Lithuania, France, Germany, the USA, Italy, Finland, and Spain. The Horizon Europe Innovation Action funds the venture with 9.5 M€.
What is ThrombUS+?
ThrombUS+ has an ambitious mission to develop an innovative wearable diagnostic device for point-of-care, operator-free, continuous monitoring of deep vein thrombosis.
Deep vein thrombosis (DVT) poses a significant health risk, with potentially life-threatening consequences when left undetected. DVT involves the formation of blood clots in deep veins, primarily in the lower limbs, leading to blood flow obstruction. Shockingly, up to two-thirds of DVT cases exhibit no clinical symptoms, making early diagnosis challenging. ThrombUS+ steps in to bridge this gap, bringing together a diverse team of experts spanning industry, technology, regulation, social science, and clinical trials.
SciGen’s role in the project is to lead communication and dissemination activities, including the data challenge and engagement of stakeholders.
Communication activities include raising awareness and sharing project information to a wide range of stakeholders and audiences, from practitioners to laypeople. To accomplish the communication goals, SciGen has created a project website, educational video, social media channels, flyer, and newsletters.
Dissemination activities begin after the conclusion of data collection. The first clinical trial has already begun enrollment and is nearing 500 participants. The results will be shared with specialized audiences such as researchers, clinicians and policymakers. The goal of disseminating the ThrombUS+ project results is to promote their use by relevant stakeholders and audiences and ensure a real-life application of the device for the benefit of patients.
About SciGen
SciGen is the company behind ePostersLive, InstaJudge, PosterGenius, ePosterScholar, and other products that have transformed modern scientific communication. SciGen’s journey began with a vision to harness technology to make scientific research more accessible, efficient and impactful. SciGen is also the inventor of the technology for electronic posters as a means of presentation at scientific conferences, which it introduced to the global market. This technology and the digital presentation of scientific (medical and academic) posters have become the most advanced and widespread method in the global scientific community. SciGen Technologies' innovative technologies were highlighted in an article by the highly reputable Nature in 2012.
Prototype shared at the latest consortium meeting
Consortium Partners:
- 1) Athena Research Center, Greece
- 2) Kaunas University of Technology, Lithuania
- 3) Vermon SA Center, France
- 4) Fraunhofer IPMS, Germany
- 5) Telemed Ultrasound Medical Systems, Lithuania
- 6) EchoNous, USA
- 7) medis Medizinische Messtechnik GmbH, Germany
- 8) ComfTech srl, Italy
- 9) Tampere University, Finland
- 10) Lietuvos sveikatos mokslų universitetas (LSMU), Lithuania
- 11) Papageorgiou General Hospital, Greece
- 12) Fondazione Casa Sollievo della Sofferenza, Italy
- 13) Hôpital Simone Veil - Groupement hospitalier Eaubonne-Montmorency, France
- 14) VDE, Germany
- 15) Medea Project, Italy
- 16) Phaze Clinical Research & Pharma Consulting S.A., Greece
- 17) PredictBy, Spain
- 18) SciGen Technologies, SA., Greece
Be sure to connect with ThrombUS+ on LinkedIn and via the newsletter to stay up-to-date with news and the latest updates.
Katerina Pavlidi, MSt
Chief Scientific Officer
Katerina works in Sales and Marketing at SciGen Technologies. She is also a college and medical school application advisor, as well as a freelance editor.